---
title: "Darzalex (daratumumab), all indications: Access and coverage questions"
description: "Access and coverage questions on Darzalex (daratumumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Patient support and Cost and coverage. Questions: What patient support is available for Darzalex (J&J withMe)? Is Darzalex covered by insurance and Medicare? Is there a Darzalex copay savings program? What are the J-codes for Darzalex and Darzalex Faspro? 4 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/darzalex/access-and-coverage"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Darzalex (daratumumab), all indications: Access and coverage questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Darzalex](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf), [Darzalex Faspro](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf)  
Indication pages: [Multiple myeloma](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma)

## Patient support

<a id="darzalex-patient-support"></a>

### What patient support is available for Darzalex (J&J withMe)?

> “Our J&J withMe program is here at every step to provide personalized support to help patients start and stay on their J&J medicines.”

Source: [DARZALEX: Multiple Myeloma Resources, captured 2026-11-12](https://www.darzalexhcp.com/multiple-myeloma-resources/#:~:text=Our%20J%26J%20withMe%20program%20is,stay%20on%20their%20J%26J%20medicines.)

> “Access Support—to help navigate payer processes.”

Source: [DARZALEX: Multiple Myeloma Resources, captured 2026-11-12](https://www.darzalexhcp.com/multiple-myeloma-resources/#:~:text=Access%20Support%E2%80%94to%20help%20navigate%20payer%20processes.)

> “Affordability Resources—to help patients discover ways to afford their DARZALEX<sup>®</sup> or DARZALEX FASPRO<sup>®</sup> medicine.”

Source: [DARZALEX: Multiple Myeloma Resources, captured 2026-11-12](https://www.darzalexhcp.com/multiple-myeloma-resources/#:~:text=Affordability%20Resources%E2%80%94to%20help%20patients%20discover,medicine.)

> “Dedicated, free 1-on-1 Care Navigator Support for Your Patients
> —offered through DARZALEX withMe to support the nonclinical needs that may arise while on DARZALEX<sup>®</sup> or DARZALEX FASPRO<sup>®</sup>”

Source: [DARZALEX: Multiple Myeloma Resources, captured 2026-11-12](https://www.darzalexhcp.com/multiple-myeloma-resources/#:~:text=Dedicated%2C%20free%201%2Don%2D1%20Care%20Navigator,or%20DARZALEX)

> “The patient support and resources provided by J&J withMe are not intended to give medical advice, replace a treatment plan from the patient’s healthcare provider, offer services that would normally be performed by the provider’s office, or serve as a reason to prescribe DARZALEX<sup>®</sup> or DARZALEX FASPRO<sup>®</sup>.”

Source: [DARZALEX: Multiple Myeloma Resources, captured 2026-11-12](https://www.darzalexhcp.com/multiple-myeloma-resources/#:~:text=The%20patient%20support%20and%20resources,or%20DARZALEX)

## Cost and coverage

<a id="darzalex-cost-insurance-savings"></a>

### Is Darzalex covered by insurance and Medicare?

> “DARZALEX FASPRO<sup>®</sup> and DARZALEX<sup>®</sup> are covered for ~97% of people with commercial insurance and ~97% of people with Medicare.<sup>7</sup>”

Source: [DARZALEX: darzalexhcp.com, captured 2026-11-12](https://www.darzalexhcp.com/for-apps-and-nurses/for-apps-and-nurses-faq/#:~:text=covered%20by%20insurance%3F-,DARZALEX,and%20~97%25%20of%20people%20with)

On the page, select: Are DARZALEX FASPRO® and DARZALEX® covered by insurance?

> “This may not represent 100% of lives due to data limitations.”

Source: [DARZALEX: darzalexhcp.com, captured 2026-11-12](https://www.darzalexhcp.com/for-apps-and-nurses/for-apps-and-nurses-faq/#:~:text=This%20may%20not%20represent%20100%25%20of%20lives%20due%20to%20data%20limitations.)

On the page, select: Are DARZALEX FASPRO® and DARZALEX® covered by insurance?

Note: The coverage figure is a manufacturer statement from the APP and nurse FAQ; the captured page does not show the source of its reference 7.

<a id="darzalex-savings-program"></a>

### Is there a Darzalex copay savings program?

> “The DARZALEX withMe Savings Program can help eligible patients save on their out-of-pocket costs for their Johnson & Johnson medicine. Depending on the patients’ health insurance plan, savings may apply toward co-pay, co-insurance, or deductible.”

Source: [DARZALEX: darzalexhcp.com, captured 2026-11-12](https://www.darzalexhcp.com/for-apps-and-nurses/additional-resources/#:~:text=The%20DARZALEX%20withMe%20Savings%20Program,toward%20co%2Dpay%2C%20co%2Dinsurance%2C%20or%20deductible.)

Note: The captured Darzalex HCP pages do not state the Savings Program’s eligibility criteria or benefit maximum.

<a id="darzalex-j-code"></a>

### What are the J-codes for Darzalex and Darzalex Faspro?

> “AVAILABLE FORMULATIONS OF DARZALEX<sup>®</sup> AND DARZALEX FASPRO<sup>®</sup>
> 100 mg single-use vial for 
> intravenous (IV) infusion
> Single-dose vial for
> subcutaneous (SC)  injection 
> 400 mg single-use vial for 
> intravenous (IV) infusion
> ADMINISTRATION  Healthcare professional-
> administered SC injection 
> HCPCS CODE        J9144
> NDC NUMBER        57894-503-01
> DISTRIBUTION      Specialty Distributor 
> 1,800 mg daratumumab and 30,000 units 
> hyaluronidase/15 mL vial
> ADMINISTRATION  Healthcare professional-
> administered IV infusion
> HCPCS CODE        J9145
> NDC NUMBER        57894-505-05
> DISTRIBUTION      Specialty Distributor 
> 100 mg daratumumab/5 mL vial 
> (20 mg/mL)
> ADMINISTRATION  Healthcare professional-
> administered IV infusion
> HCPCS CODE        J9145 
> NDC NUMBER        57894-505-20
> DISTRIBUTION      Specialty Distributor 
> 400 mg daratumumab/20 mL vial 
> (20 mg/mL)”

Source: [DARZALEX: cp-136512v5_darzalex-darzalex-faspro-specialty-distributor-list.pdf, page 2, captured 2026-11-12](https://www.darzalexhcp.com/pdfs/cp-136512v5_darzalex-darzalex-faspro-specialty-distributor-list.pdf#page=2)

Note: The passage is from the specialty distributor list that the Multiple Myeloma Resources page of the Darzalex HCP site links. Each entry lists administration, HCPCS code, NDC number, and distribution, followed by the vial strength: 1,800 mg daratumumab and 30,000 units hyaluronidase (DARZALEX FASPRO, J9144), then 100 mg and 400 mg daratumumab (DARZALEX, J9145).

## Related pages
- [Medical information: Darzalex (daratumumab): All indications](https://www.evicenter.com/medical-information/darzalex)
